Bristol CEO says Gilead holding out on hep C tie-up

Bristol-Myers Squibb ($BMY) isn't giving up on pushing Gilead Sciences ($GILD) to move ahead with further study of the two companies' oral drugs as a combo treatment for the hepatitis C virus, with Br…
Read the full story: News